Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.46 Insider Own11.58% Shs Outstand43.55M Perf Week26.56%
Market Cap282.20M Forward P/E- EPS next Y-1.22 Insider Trans0.76% Shs Float38.50M Perf Month79.01%
Income-88.33M PEG- EPS next Q-0.29 Inst Own60.81% Short Float / Ratio1.08% / 3.64 Perf Quarter163.41%
Sales16.93M P/S16.67 EPS this Y44.00% Inst Trans-0.43% Short Interest0.42M Perf Half Y130.60%
Book/sh3.53 P/B1.83 EPS next Y20.56% ROA-38.67% Target Price10.60 Perf Year208.57%
Cash/sh4.95 P/C1.31 EPS next 5Y- ROE-61.85% 52W Range1.45 - 7.15 Perf YTD318.06%
Dividend- P/FCF- EPS past 5Y- ROI-35.27% 52W High-9.37% Beta0.82
Dividend %- Quick Ratio6.56 Sales past 5Y289.37% Gross Margin67.14% 52W Low346.90% ATR0.62
Employees137 Current Ratio6.56 Sales Q/Q15.58% Oper. Margin-535.94% RSI (14)71.12 Volatility15.47% 14.13%
OptionableNo Debt/Eq0.51 EPS Q/Q64.06% Profit Margin-521.63% Rel Volume1.42 Prev Close6.53
ShortableYes LT Debt/Eq0.48 EarningsNov 09 BMO Payout- Avg Volume114.45K Price6.48
Recom1.17 SMA2034.99% SMA5069.23% SMA200125.47% Volume162,850 Change-0.77%
Date Action Analyst Rating Change Price Target Change
Jun-22-23Initiated Wedbush Outperform $8
Dec-01-23 09:55AM
Nov-30-23 07:00AM
Nov-27-23 12:00PM
Nov-20-23 08:50AM
Nov-15-23 12:00PM
09:55AM Loading…
Nov-09-23 08:25AM
Nov-06-23 07:00AM
Nov-02-23 09:05AM
Oct-12-23 12:00PM
Sep-27-23 09:06AM
Sep-12-23 08:00AM
Sep-05-23 07:00AM
Aug-29-23 07:00AM
12:00PM Loading…
Aug-16-23 12:00PM
Aug-10-23 08:25AM
Jul-13-23 07:25AM
Jun-29-23 07:00AM
Jun-15-23 07:42AM
Jun-06-23 07:00AM
Jun-01-23 04:10PM
May-26-23 12:37AM
May-25-23 04:06PM
May-24-23 04:13PM
May-17-23 04:35PM
07:33AM Loading…
May-11-23 07:33AM
May-10-23 08:15AM
May-09-23 01:29PM
May-02-23 04:42PM
Apr-10-23 07:00AM
Mar-31-23 08:00AM
Mar-14-23 07:00AM
Mar-13-23 04:05PM
Mar-10-23 05:12AM
Mar-08-23 07:00AM
Mar-01-23 07:00AM
Feb-21-23 07:00AM
Jan-23-23 07:00AM
Jan-20-23 05:35AM
Jan-05-23 07:00AM
Dec-12-22 07:00AM
Dec-09-22 06:09AM
Dec-01-22 08:00AM
Nov-22-22 07:00AM
Nov-11-22 07:00AM
Nov-09-22 07:00AM
Nov-07-22 07:00AM
Nov-03-22 09:34AM
Oct-05-22 08:33AM
Sep-28-22 09:21AM
Sep-22-22 07:00AM
Sep-12-22 07:00AM
Sep-07-22 07:00AM
Aug-13-22 08:14AM
Aug-12-22 06:08AM
Aug-10-22 07:00AM
Aug-05-22 11:58AM
Aug-03-22 07:00AM
Jul-11-22 07:00AM
Jul-07-22 07:00AM
Jul-06-22 08:28AM
Jun-22-22 07:00AM
Jun-02-22 07:00AM
May-31-22 07:00AM
May-22-22 08:03AM
May-19-22 07:00AM
May-17-22 07:00AM
May-12-22 07:00AM
May-09-22 07:00AM
May-05-22 10:25AM
May-02-22 05:02PM
Apr-11-22 07:00AM
Mar-09-22 07:00AM
Mar-02-22 07:00AM
Feb-18-22 12:39PM
Feb-10-22 07:00AM
Jan-24-22 12:30PM
Jan-10-22 07:00AM
Dec-20-21 01:36PM
Dec-13-21 09:16AM
Dec-03-21 07:00AM
Dec-02-21 07:00AM
Nov-11-21 07:00AM
Nov-10-21 07:00AM
Nov-04-21 09:30AM
Nov-01-21 09:11AM
Oct-19-21 02:43PM
Oct-15-21 10:56AM
Oct-05-21 07:00AM
Sep-28-21 07:00AM
Sep-09-21 04:05PM
Sep-02-21 07:00AM
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARBERICH TIMOTHY JDirectorJun 02Buy2.6337,88099,56437,880Jun 06 07:53 PM
Lynx1 Capital Management LP10% OwnerMay 31Sale2.5225,40063,9525,224,600Jun 02 05:35 PM
Silver Brian M.Chief Financial OfficerDec 28Buy1.563,1584,94132,885Dec 29 02:34 PM
Silver Brian M.Chief Financial OfficerDec 27Buy1.502,8424,27629,727Dec 29 02:34 PM